PAUL DAVID ZITO MBBS NPI 1396155966

NPI Details

Paul David Zito, MBBS is an internal medicine in Austin, TX with 13 years of experience. The provider is a physician who provides long-term, comprehensive care in the office and the hospital, managing both common and complex illness of adolescents, adults and the elderly. Internists are trained in the diagnosis and treatment of cancer, infections and diseases affecting the heart, blood, kidneys, joints and digestive, respiratory and vascular systems. They are also trained in the essentials of primary care internal medicine, which incorporates an understanding of disease prevention, wellness, substance abuse, mental health and effective treatment of common problems of the eyes, ears, skin, nervous system and reproductive organs. Paul David Zito, MBBS NPI is 1396155966. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

The provider's business location address is:

601 E 15TH ST
UT SOUTHWESTERN INTERNAL MED, UNIVERSITY MED CENTER
AUSTIN, TX
ZIP 78701-930
Phone: (512) 324-8355

The NPI 1396155966 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml (HCPCS:Q9967)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram (HCPCS:Q5110)
• Injection, azacitidine, 1 mg (HCPCS:J9025)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, paclitaxel protein-bound particles, 1 mg (HCPCS:J9264)
• Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg (HCPCS:Q5118)
• Injection, docetaxel, 1 mg (HCPCS:J9171)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units (HCPCS:Q5106)
• Injection, lanreotide, 1 mg (HCPCS:J1930)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
• Injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg (HCPCS:Q5116)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Injection, pegfilgrastim-apgf, biosimilar, (nyvepria), 0.5 mg (HCPCS:Q5122)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Uric acid level, blood (HCPCS:84550)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Magnesium level (HCPCS:83735)
• Phosphate level (HCPCS:84100)
• Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml (HCPCS:A9579)
• Injection, fulvestrant, 25 mg (HCPCS:J9395)
• Injection, bortezomib, not otherwise specified, 0.1 mg (HCPCS:J9044)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Cyclophosphamide, 100 mg (HCPCS:J9070)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Ct scan of chest with contrast (HCPCS:71260)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Ct scan of abdomen and pelvis with contrast (HCPCS:74177)
• Unclassified drugs (HCPCS:J3490)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Blood creatinine level (HCPCS:82565)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries (HCPCS:A9552)
• Nuclear medicine study from skull base to mid-thigh with ct scan (HCPCS:78815)
• Ferritin (blood protein) level (HCPCS:82728)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Reticulated (young) platelet measurement (HCPCS:85055)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Blood test, clotting time (HCPCS:85610)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Telephone medical discussion with physician, 5-10 minutes (HCPCS:99441)
• Mri scan of brain before and after contrast (HCPCS:70553)
• Urine microalbumin (protein) analysis (HCPCS:82044)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Coagulation assessment blood test, plasma or whole blood (HCPCS:85730)
• Red blood count, automated test (HCPCS:85045)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Ct scan of soft tissue of neck with contrast (HCPCS:70491)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Nuclear medicine study whole body with ct scan (HCPCS:78816)
• Nuclear medicine study of heart pumping function by labeling red blood cells with measurement of internal blood volume ejected with every beat over multiple cycles (HCPCS:78472)
• Telephone medical discussion with physician, 11-20 minutes (HCPCS:99442)
• New patient office or other outpatient visit, 30-44 minutes (HCPCS:99203)
• Technetium tc-99m labeled red blood cells, diagnostic, per study dose, up to 30 millicuries (HCPCS:A9560)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Ct scan of chest without contrast (HCPCS:71250)

The enumeration date for this NPI number is 5/5/2014 and was last updated on 7/27/2021.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: